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Together
we heal
How the Leading Together 
campaign is turning 
hope into reality
W I N T E R  2 0 1 8 - 1 9
A letter from the dean 
When I came to Washington University School of Medicine as executive vice chancellor and dean in 2015, Leading 
Together was charging full steam ahead. It was inspiring to see 
philanthropic support for the school, already at a remarkable 
level, soar to even greater heights. I am deeply grateful to 
everyone involved in the campaign for joining with us to  
pursue the vision of advancing human health.
I’d like to take a moment to thank members of the 
Washington University Board of Trustees, the School of 
Medicine National Council, the School of Medicine campaign 
committee, our Eliot Society committee, the Washington 
University Medical Center Alumni Association executive 
council, and the many other alumni volunteers who provided crucial 
leadership during the campaign. You helped steer the School of Medicine 
through the campaign’s goals and successful conclusion.   
We face clear challenges as we look to the future of medicine. However, 
we also are poised to continue exceptional work and to make bold moves that 
will keep the School of Medicine at the forefront of biomedicine and health 
care. Many, many donors — from our loyal annual fund supporters, to those 
who invest in the leaders of tomorrow through scholarships, to those who 
have made a significant impact on faculty by funding research, professorships, 
facilities and centers — have made this possible. These individuals have 
helped position us to explore new partnerships, rethink our curriculum for 
new generations, build our excellent faculty practice, enhance and improve 
diversity, develop physician-scientists, and improve the already extraordinary 
breadth and depth of our collaborative research. This will translate into 
discoveries that will ultimately benefit patients here and around the world. 
Together, we can pursue a future in which discoveries reach patients 
sooner. Together, we can realize the dream of personalized medicine. Together, 
we can continue to generate the resources needed to transform health care. 
Thank you for giving us the momentum to aim for the highest of ideals at 
Washington University School of Medicine. It’s an amazing place to be, and 
I’m so excited and fortunate to be a part of it.
Sincerely,
David H. Perlmutter, MD
George and Carol Bauer Dean, School of Medicine
Spencer T. and Ann W. Olin Distinguished Professor
Executive Vice Chancellor for Medical Affairs
Washington University School of Medicine   
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Together, we heal.
This issue of Outlook is a special one.  It documents the conclusion of Leading Together:  
The Campaign for Washington University.
The campaign, which ended this summer, raised an 
unprecedented $1.85 billion for the School of Medicine in the 
most successful campaign in school history. The campaign has 
established 281 endowed scholarships, produced 73 named 
professorships, and generated $1.34 billion for research.
These contributions have huge real-life import. They allow 
gifted students to attend a world-class medical school and learn 
from extraordinary faculty. And they allow leading researchers to 
find solutions for some of medicine’s most intractable problems. 
Those things are happening now, and, because of the generosity 
of donors, will continue to happen.
In this issue, we’ll look at four areas of research the  
campaign has significantly advanced. They are:
We’ll introduce you to the researchers who are advancing 
medicine in these areas, and, because the campaign was about 
looking forward, we’ll show you what the future holds. 
Alzheimer’s
Prevention, early 
diagnosis and treatment 
of Alzheimer’s disease 
Mental illness
New medications for 
mental illnesses, such 
as depression, anxiety 
and schizophrenia
Cancer
Targeted therapies  
that harness the 
patient’s own immune 
system to fight cancer 
Microbiome
Improved understanding 
of the human microbiome 
to address a host of 
health problems
Winter 2018-19
Caring for an aging relative with Alzheimer’s disease, 
watching memories slowly slip away, is an exhausting  
and heartbreaking ordeal. For those with the condition, 
modern medicine can offer little in the way of treatment  
as the disease inexorably strips away their ability to  
recognize and understand the world around them. 
Finding solutions can’t happen soon enough. The 
American population is rapidly graying, and the risk  
of developing the disease rises with advancing age.  
The Alzheimer’s Association predicts that 16 million 
Americans will be living with the disease by 2050. 
A large, dedicated team at Washington University  
School of Medicine has been working for 40 years to 
brighten this bleak outlook, and the investigators may be on  
the cusp of succeeding. They have traced the natural history  
of the disease, studied the molecular and cellular changes 
that occur in the brain, designed and tested investigational 
drugs aimed at slowing or stopping the disease, and 
developed imaging techniques to detect toxic proteins in  
the brain. Now, they are on the brink of finding ways to 
predict who will get the disease and when; they may even 
determine how to prevent it entirely. 
An Alzheimer’s-free future has never looked more likely. 
New hope for 
old disease
Doctors may soon be able to predict,  
prevent Alzheimer’s disease
B Y  T A M A R A  B H A N D A R I
4  Washington University School of Medicine
outlook.wustl.edu Outlook  5
Randall J. Bateman, MD, examines 
Taylor Hutton, a participant in a 
global multicenter study testing 
drugs that may delay or prevent 
Alzheimer’s onset. An active 
Alzheimer’s advocate, Hutton 
attends and speaks at awareness 
events and wears an Alzheimer’s 
awareness tattoo on her foot. 
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Step one: diagnosis
The first sign is usually forgetfulness — a forgotten 
conversation, a misplaced item, a question asked 
and answered and asked again. Until a few decades 
ago, such lapses might have been chalked up to the 
normal effects of aging. But Leonard Berg, MD, a 
professor of neurology at Washington University, 
was concerned that the distinction between normal 
aging and dementia was poorly understood, so in 
1972 he started a faculty lunch group to discuss 
how to distinguish the two processes. 
“At the time, there was no standard method 
to distinguish normal aging from very mild 
dementia,” said John C. Morris, MD, the Harvey 
A. and Dorismae Hacker Friedman Distinguished 
Professor of Neurology and professor of pathology 
and immunology. “So Leonard and his colleagues 
developed a clinical tool to diagnose dementia and 
to determine its severity.”
That tool, the Clinical Dementia Rating Scale, 
later revised by Morris, is now used worldwide 
to identify people with dementia. Berg died in 
2007; but the work he started has since grown into 
Washington University’s Charles F. and Joanne 
Knight Alzheimer’s Disease Research Center 
(Knight ADRC), a network, directed by Morris,  
of faculty members, trainees and staff dedicated to 
understanding, treating and preventing the No. 1 
cause of cognitive decline in older people. 
Today, we know that memory lapses could be 
caused by many things: lack of sleep, medications, 
vitamin deficiencies, brain tumors or neurological 
diseases other than Alzheimer’s, such as Parkinson’s 
disease or frontotemporal dementia. 
“When people come in and they’re clearly 
impaired but we don’t know what the cause is, 
that’s when biomarkers can be really useful,” 
said Anne Fagan, PhD, a professor of neurology 
and head of the biomarker research unit at the 
Knight ADRC. Biomarkers are proteins or other 
biomolecules that indicate the presence of disease. 
Research by Fagan and others has established 
that two proteins linked to Alzheimer’s disease 
— amyloid beta and tau — can be detected in the 
cerebrospinal fluid that bathes the brain and spinal 
cord. Neurologists can resolve a difficult diagnosis 
by taking a spinal tap and measuring levels of the 
two proteins.
“I use the results of these biomarker tests to 
inform the care of my patients,” said Gregory S. 
Day, MD, an assistant professor of neurology. 
“A few decades ago, Alzheimer’s was formally 
diagnosed only on autopsy. Now using biomarkers 
or imaging, we can tell people what is going on 
very early in the process.”
Stopping the disease 
in its tracks 
Early detection allows physicians to discuss 
lifestyle modifications and financial arrangements 
with patients. It does not, however, allow them to 
offer any medications to slow or stop the disease. 
The Food and Drug Administration has not yet 
approved any such drugs.
Research by David M. 
Holtzman, MD, has 
focused on how levels of 
the Alzheimer’s proteins 
amyloid beta and tau in 
the brain and spinal fluid 
are linked to risk for and 
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whose dementia is not related to amyloid with an 
amyloid drug, of course it’s not going to work.” 
Now, clinical trials routinely screen for 
misdiagnosed participants using amyloid PET 
scans or biomarker analysis. 
In addition, researchers are expanding the basic 
science foundation upon which drug development 
rests. But much of what we know about Alzheimer’s 
disease has been learned from studying only one 
part of the American population.
“There is a lot of mistrust in the African-
American community because of a history of 
David M. Holtzman, MD, the Andrew B. and 
Gretchen P. Jones Professor, head of the Department 
of Neurology and professor of developmental 
biology, is trying to change that. He studies the  
basic biology underlying Alzheimer’s disease —  
how amyloid beta and tau build up in the brain, 
why clumps of such proteins cause brain cells to 
die, and how drugs can be designed to interrupt the 
process. The research of Holtzman and colleagues 
at Eli Lilly and Company led to the development of 
solanezumab, a drug designed to counter amyloid 
beta’s toxic effects. Solanezumab and another drug, 
gantenerumab, are now being evaluated in the first-
ever Alzheimer’s disease prevention trial, at the 
School of Medicine and elsewhere. 
Other drugs — targeting amyloid beta or tau — 
also are being tested, and researchers are hopeful 
that some will prove effective. 
In the past, drug trials were complicated by a 
lack of accurate disease detection methods. 
Then in the early 2000s, Tammie L.S. 
Benzinger, MD, PhD, the Knight ADRC’s director 
of imaging studies, and others pioneered the use 
of positron emission tomography (PET) brain 
scans targeted against amyloid beta as a tool for 
detecting Alzheimer’s.
“When people started using amyloid PET to 
assess trial participants, they discovered that only 
about 80 percent of the participants actually had 
Alzheimer’s,” said Benzinger, a professor of radiology 
and of neurological surgery. “If you treat someone 
Tammie L.S. Benzinger, 
MD, PhD, prepares to  
scan a patient with 
PET imaging. She and 
colleagues pioneered  
the use of PET to  
detect Alzheimer’s.  
Charles F. and Joanne Knight’s extraordinary campaign 
support included a major commitment to name The 
Charles F. and Joanne Knight Alzheimer’s Disease 
Research Center.
Researchers here are pursuing treatments 
that could one day dramatically improve 
the lives of millions of individuals 
worldwide. We want to do our part to 
fulfill that goal.”   
  —  the late Charles F. Knight, former Trustee
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“We’ve found that the concentration of 
tau protein is significantly lower in African-
Americans than in non-Hispanic whites,” Morris 
said. “What does that mean in terms of the 
pathology of the disease? I don’t know. But I do 
know it means that we can’t just take everybody 
and lump them together. The disease may develop 
and progress differently in different populations. 
We are not going to find treatments that work for 
all people if we don’t understand how the disease 
behaves in all people.”
Detecting the silent phase
Although treatment is important for the 
estimated 5 million Americans already living 
with Alzheimer’s, it won’t lead to a future free 
of Alzheimer’s. By the time people show up in 
doctors’ offices complaining of forgetfulness, their 
brains already have begun to atrophy. And while 
some of the drugs currently in trials may be able 
to prevent more brain cells from dying, nothing 
will bring back the cells already lost.
To truly stop Alzheimer’s, doctors must catch 
people heading down the path to Alzheimer’s 
dementia and redirect them, much as physicians 
today measure blood cholesterol levels and, if 
necessary, prescribe cholesterol-lowering drugs  
to avert a heart attack.
Since the early 1990s, Washington University 
researchers have been collecting evidence that 
memory loss and confusion show up very late in 
the game, after years of toxic protein accumulation 
in the brain and corresponding tissue damage. 
Two major studies led by Washington University 
have used imaging and biomarker analysis to 
trace the natural history of the disease: the Adult 
Children Study, which follows people with at 
least one parent diagnosed with Alzheimer’s, and 
the Dominantly Inherited Alzheimer Network 
(DIAN), which studies people genetically 
predisposed to develop the disease at a young 
age. These two studies, and others conducted 
at Washington University and elsewhere, have 
allowed researchers to develop a rough timeline 
of what happens in the brain in the years before 
symptoms appear: Amyloid plaques appear first, 
then tau tangles, followed by brain atrophy. 
“This silent phase may last two decades, which 
gives us a chance to intervene,” Morris said. 
Spinal taps and PET scans can reliably detect 
signs of disease before dementia, but neither is 
ideal for widespread screening. A single PET scan 
Anne Fagan, PhD, 
observes staff scientist 
Matthew R. Amos as he 
processes samples in her 
lab. Fagan has identified a 
number of biomarkers for 
Alzheimer’s disease.
medical exploitation,” said Myrtis E. Spencer, 
who leads the Knight ADRC’s African-American 
outreach program. “But they are twice as likely 
to get the disease compared with non-Hispanic 
whites. We don’t know why. We don’t have the 
full scientific picture because research historically 
hasn’t been inclusive.”
Through the efforts of Spencer, Morris and 
others, African-American participation in 
Alzheimer’s studies at the School of Medicine has 
risen to 18 percent, comparable with the African-
American population in the St. Louis area and 
significantly higher than the national average for 
Alzheimer’s studies.  
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costs approximately $5,000 and requires equipment 
and expertise difficult to find outside of research 
settings. Spinal taps have an undeserved reputation 
for being painful and dangerous, so some patients 
are reluctant to undergo the procedures.
MRI scans, though, are already a routine part 
of neurological care, available in most clinics. 
Benzinger and colleagues have shown that a 
characteristic pattern of brain atrophy is visible in 
an MRI scan before symptoms appear. They are 
developing an MRI scan to diagnose Alzheimer’s 
in its pre-symptomatic phase.
A blood test is also on the horizon. “Last year my 
lab reported the first highly specific blood test for 
amyloid,” said Randall J. Bateman, MD, the Charles 
F. and Joanne Knight Distinguished Professor of 
Neurology. “Since then, other groups have replicated 
and expanded on it. I think we’ll see that test in use 
in doctor’s offices in the next three to five years.”
Rajendra S. Apte, MD, PhD, the Paul A. Cibis 
Distinguished Professor of Ophthalmology and 
Visual Sciences, and Gregory P. Van Stavern, MD, 
a professor of ophthalmology and visual sciences, 
recently have reported a small study that suggests 
that signs of Alzheimer’s might be detectable 
through a specialized, noninvasive eye exam.
No longer inevitable 
But finding people on the path to dementia is only 
half the battle. We also need to find a way to get 
them off the path. 
Bateman directs the DIAN Trials Unit 
(DIAN-TU), an international clinical trial designed 
to find drugs that prevent Alzheimer’s dementia. 
The trial involves people from DIAN families; 
family members who inherit a faulty gene variant 
are all but guaranteed to develop Alzheimer’s 
dementia at about the same age their parent did, 
typically in their 50s, 40s or even 30s. Participants 
enroll in the trial while their minds are still sharp 
but their brains show some amyloid accumulation. 
Two drugs are being tested — the trial of a third 
was stopped due to safety issues — to determine 
whether they can slow amyloid plaque buildup.  
The final report is due out in a year.
Although DIAN-TU involves people with rare 
mutations, treatments that are successful in this 
population could also help people with the more 
common forms of the disease, which strike older 
adults. It is thought that the destructive processes 
in the brain are much the same for both types of 
the disease. 
Other prevention trials involving people with 
genetic forms of Alzheimer’s are in the works. 
A few prevention trials are underway in people 
without genetic forms of the disease, and more 
could be launched once screening tests are more 
fully developed. There are plenty of experimental 
drugs to try.
Shakespeare lamented the coming of the 
“second childishness.” We may be able to  
elude it.
David C. Farrell and his late wife, Betty, made major 
commitments to establish and enhance the Farrell 
Family Alzheimer’s Disease Research Fund, supporting 
the research of David M. Holtzman, MD.
Myrtis E. Spencer, 
conferring here with 
pioneering Alzheimer’s 
researcher John C. Morris, 
MD, leads an outreach 
effort dedicated to ensuring 
that African-Americans are 
appropriately represented 
in Alzheimer’s research.
One day, Alzheimer’s disease will be treatable or even 
preventable. Researchers at Washington University are 
leading the way to making that bright future real.”                





Physician-scientists aim to reduce the impact of mental illness on society
B Y  J I M  D R Y D E N
Up to one-third of the 16 million Americans with clinical depression 
don’t get relief from antidepressant drugs. As a result, they endure 
continuing sadness, problems with sleep, and often, difficulty 
concentrating, so that reading a book or functioning at work is 
problematic. Some even contemplate and attempt suicide. And the 
impact extends to family and friends.
10  Washington University School of Medicine
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The Taylor Family Institute, a 
collection of several member 
research laboratories, is studying 
the potential therapeutic 
value of natural and synthetic 
neurosteroids, which act on 
receptors in the brain to affect 
cognitive and emotional functions. 
Outlook  11
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For doctors treating patients with depression and other psychiatric disorders, the reality is that many of the therapeutic drugs at 
their disposal have major limitations — both in 
terms of effectiveness and potential adverse side 
effects. Not only that, but the last new class of 
antidepressant drugs, selective serotonin reuptake 
inhibitors (SSRIs) such as Paxil, Zoloft, Lexapro 
and Prozac, hit the market 30 years ago. 
At Washington University’s Taylor Family 
Institute for Innovative Psychiatric Research, 
investigators are looking for new solutions. Their 
ultimate goal: Reduce suffering and diminish  
the impact of psychiatric illnesses on society. 
Institute investigators are exploring receptors 
in the brain to identify new targets for therapy, 
developing potential drug candidates, and partnering  
with industry to speed progress. The institute is  
on the verge of helping get two investigational 
antidepressant drugs to the market, and there 
could be other promising compounds in the 
pipeline, too. 
Private funding =  
fast progress
The institute was created in 2012 through private 
funding from the university’s Leading Together 
campaign. Its founding mission: to provide flexible 
funding to foster and streamline efforts in basic 
research, clinical research and drug development 
as scientists work across disciplines to uncover 
new ways to treat psychiatric illness. Members of 
the institute collaborate among several 
departments, including psychiatry, anesthesiology, 
developmental biology, radiology and neurology. 
“The institute really was founded on the 
premise that we need flexible funding to support 
pipelines of research development, rather than 
focusing on individual projects in specific 
departments,” said Steven J. Mennerick, PhD, a 
professor of psychiatry and of neuroscience and 
the institute’s scientific director. “Government 
grants tend to be very specific, so to take a project 
to the next step, you need another grant, and then 
another. But with flexible funding through the 
institute, we can partner — quickly — with people 
who have expertise in other areas of science or 
Steven J. Mennerick, PhD, 
prepares to use a collection 
of technology — including 
a microscope and amplifiers 
— to measure the tiny 
electrical impulses between 
brain cells. The equipment 
helps him assess how the 
electrical conversations of 
neurons are influenced by 
therapeutic drugs.
In its 25 years of existence, 
the YSP has connected with 
more than 10,000 students, 
encouraging many to consider 
STEM (science, technology, 
engineering, math) careers. 
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Up to one-third of the 16 million Americans with clinical depression don’t 
get relief from antidepressant drugs. 
As a result, they endure continuing 
sadness, problems with sleep, and 
often, difficulty concentrating, so that 
reading a book or functioning at work 
is problematic. Some even contemplate 
and attempt suicide. And the impact 
extends to family and friends.
For doctors treating patients with 
depression and other psychiatric 
disorders, the reality is that many of the 
therapeutic drugs at their disposal have 
major limitations — both in terms of 
effectiveness and potential adverse side 
effects. Not only that, but the last new 
class of antidepressant drugs, selective 
serotonin reuptake inhibitors (SSRIs) 
such as Paxil, Zoloft, Lexapro and 
Prozac, hit the market 30 years ago. 
At Washington University’s Taylor 
Family Institute for Innovative 
Psychiatric Research, investigators 
are looking for new solutions. Their 
ultimate goal: Reduce suffering and 
diminish the impact of psychiatric 
illnesses on society.
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Andrew C. and Barbara Taylor, and the family’s Crawford Taylor 
Foundation, made major commitments to establish and enhance 
the Taylor Family Institute for Innovative Psychiatric Research.
I have received notes from people 
around the country who have been 
impacted by mental illness. They now 
have a sense of hope; someone is paying 
attention. I want many people to pay 
attention, because I think awareness 
promotes momentum.”
 —  Andrew C. Taylor, Life Trustee; Chair,  
Leading Together campaign
drug development, and we can make progress 
faster than is possible with traditional grants.”
Their work starts with understanding the 
genetics and biology of psychiatric illness, as  
well as the brain circuits involved. Then, when  
basic science reveals a potential new therapeutic  
approach, institute investigators can get their 
findings into the hands of collaborators in  
private industry very quickly, especially  
through the institute’s close relationship  
with Massachusetts-based biopharmaceutical 
company Sage Therapeutics.
   
A new treatment target
Much of the focus at the institute today is directed 
toward a class of compounds called neurosteroids 
— chemicals that occur naturally in the brain and 
are involved in brain networks used for cognition, 
emotion and motivation. Disruptions in 
neurosteroid levels can contribute to mood 
disorders such as depression, anxiety disorders, 
schizophrenia, alcoholism, sleep disorders, chronic 
pain, epilepsy and neurodegenerative illnesses 
such as Alzheimer’s disease.
Current evidence suggests that stress and 
disorders such as depression affect neurosteroid 
production in the brain, so institute scientists 
believe that replacing or enhancing these depleted 
steroids may alleviate that stress response to make 
the brain function more normally.
Although the institute only has bee  around for 
a handful of years, some of its members have been 
studying natural and synthetic neurosteroids for 
several decades. That work began in 1993, when 
Douglas F. Covey, PhD, then a professor of 
molecular biology and pharmacology, and Charles 
F. Zorumski, MD, then an associate professor of 
psychiatry, were part of a Program Project Grant 
from the National Institutes of Health (NIH) to 
study neurosteroids for their anesthetic effects. 
Their process: Covey’s lab synthesized neurosteroid 
molecules, and Zorumski tested th m in brain cells. 
“In those early days, we mostly were trying to 
learn about whether these molecules had anesthetic 
effects, and if so, how they might work,” said 
Covey, a professor of developmental biology, of 
anesthesiology and of psychiatry. They discovered 
that neurosteroids weren’t working through 
serotonin receptors the way SSRIs did. Instead, 
many were influencing gamma- minobutyric acid 
(GABA) receptors, the same neuronal receptors 
affected by anesthetics. 
Fast-forward about 20 years. By the spring of 
2012, Covey had made hundreds of synthetic 
neurosteroids, some of which seemed to have the 
potenti l to lleviate symptoms of depression.  
And Zorumski, now the Samuel B. Guze Professor, 
head of the Department of Psychiatry and professor 
of neuroscience, believed that after years of making 
and testing neurosteroids, they had a good handle 
on how the molecules interacted with two types of 
receptors in the brain: GABA receptors and excitatory 
glutamate receptors. They could, he thought, be on 
the verge of identifying neurosteroids to alleviate 
depression and other psychiatric disorders. 
“Some of these neuroactive steroids were potent 
anesthetics, but we believed others were going to 
prove to be useful for treating several psychiatric 
disorders,” Covey said. 
But at just about that time, a letter arrived  
from NIH announcing that the program project 
group was about to lose its funding. 
Within a day or two of receiving the bad news, 
Zorumski started drafting a new white paper, 
attempting to explain the importance and 
potential impact of the project he’d been involved 
in for two decades. 
“It was written around the time that Doug 
Covey and I were just starting to interact with 
Sage Therapeutics, and it was built around the idea 
that we could take neurosteroids — as well as the 
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Douglas F. Covey, PhD, left, 
Charles F. Zorumski, MD, and 
colleagues have spent decades 
conducting groundbreaking 
research on the therapeutic 
potential of neurosteroids.
synthetic molecules that had been developed here 
at Washington University — and turn them into 
therapies,” he said. “We weren’t entirely sure what 
these molecules actually would treat, but epilepsy 
was a clear target, so was insomnia, and so was 
postpartum depression.”
The proposals in the white paper eventually 
received funding, and the Taylor Family Institute 
for Innovative Psychiatric Research was born. 
On the verge
The results are impressive. 
“We’re literally only about six years from  
when the institute was created, and there already 
could be new drugs coming to market just several 
months from now,” said Zorumski, now the 
director of the institute. 
Sage is seeking Food and Drug Administration 
approval of two neurosteroids that it developed 
based on Washington University research: an  
IV drug called brexanalone to treat post-partum 
depression, and an oral drug known as Sage  
217 for clinical depression in men and women. 
During the Taylor Institute’s first half decade  
of existence, its scientists have published more 
than 60 scientific papers. They have continued to 
prepare new compounds to enlarge the original  
set of over 700 compounds, and multiple U.S. and 
foreign patents are pending. In collaboration, 
investigators at Taylor Institute and Sage are 
discovering and applying ways to optimize these 
neurosteroids for therapeutic use in humans. 
Covey, who has patented many of the molecules 
developed in his lab, served for a time as a partner 
at Sage, and Zorumski serves on the company’s 
scientific advisory board. As a result, much care 
has been taken to avoid conflicts of interest, so a 
good deal of the clinical testing of neurosteroid 
molecules has occurred at other centers.  
But other clinical research is underway at the 
institute. For example, institute researchers have 
been involved in clinical testing of anesthetic 
drugs, such as ketamine and nitrous oxide, as 
treatments for depression. Their common goal, 
one way or another, is to find new ways to provide 
relief to the many individuals, families and friends 
living with the effects of psychiatric illnesses. 
“The success of the Taylor Family Institute 
demonstrates the critical impact of private 
philanthropy on Washington University’s efforts to 
improve human health,” said David H. Perlmutter, 
MD, executive vice chancellor for medical affairs 
and the George and Carol Bauer Dean at the 
School of Medicine. “The investment to launch the 
institute was instrumental in helping our scientists 
make discoveries that hold great promise for 
ameliorating the burden of mental illness, and 
their continued support will bolster our ability to 
work on the therapeutic frontiers of psychiatry.”
Charles F. Zorumski, MD, is a scientific advisor for Sage Therapeutics and receives 
compensation and stock equity from the company for this role. Research partner-
ships between Sage Therapeutics and Washington University are managed in 
accordance with applicable conflict-of-interest policies and regulations. Douglas F. 
Covey, PhD, has an issued patent and pending patents for jointly invented intellectual 




Taylor Family Institute investigators are setting their 
sights on a new set of therapeutic targets in the brain. 
Their goal: Develop drugs that engage these new targets 
and better address depression and other mental illnesses.
Then
Target serotonin receptors. 
Administer selective serotonin 
reuptake inhibitors (SSRIs) and 
tricyclic drugs, which increase brain 
levels of serotonin and promote 
feelings of well-being.
PROS
Existing SSRIs and tricyclics are 
effective for many people.
CONS
Drugs can have undesirable side 
effects. Up to one-third of patients 
are not helped by these drugs.
Now
Target GABA and glutamate receptors.
Generate and test compounds that augment 
the action of gamma-aminobutyric acid 
(GABA), which calms key brain cells, and 
glutamate, which excites key brain cells. 
Seek ways to balance their activities to 
achieve well-being.
PROS
The prevalence of, and variations in, 
GABA and glutamate receptors may 
facilitate targeting specific receptor 
classes for more effective therapies.
CONS
The landscape is complex and not 
thoroughly understood. Defining a 
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A few short decades ago, cancer treatment 
consisted mainly of three pillars: surgery, 
radiation and chemotherapy. Although  
each has earned its place as a valuable 
option, more precise alternatives have long 
been the oncologist’s dream.
Now, a deeper understanding of the 
way our bodies fight disease is launching a 
promising new era in which cancer’s worst 
enemy may be the warrior within: our 
own immune system. By determining the 
characteristics of individual tumors at the 
genetic and molecular levels, researchers are 
tailoring treatment to each patient, aiming 
the built-in destructive power of the immune 




The future of cancer treatment
B Y  G A I A  R E M E R O W S K I
Robert D. Schreiber, PhD, right, consults with doctoral student 
Samuel O. Ameh. Their work exploring the immune system’s 
role in controlling cancer is fueling development of a range of 
approaches to cancer immunotherapy.
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A seismic shift
Until the early 2000s, researchers only dreamed 
that the immune system could be capable of 
keeping cancer at bay. Then research at Washington 
University and elsewhere began uncovering 
evidence that made the dream seem possible.
The shift began in 2001, when Washington 
University’s Robert D. Schreiber, PhD, and 
colleagues published a landmark paper in Nature 
concerning the adaptive immune system — the part 
of the immune system that recognizes and destroys 
specific disease-causing agents. They showed that 
mice lacking adaptive immunity developed more 
tumors, showing that conversely, healthy adaptive 
immunity restrains cancer development. 
His subsequent work demonstrated that tumors 
can evolve to evade and resist the adaptive immune 
response, which is why cancer can form in people 
with intact immunity. So, Schreiber surmised, if we 
could retrain the immune system to see cancer, we 
might have a new targeted tool to fight the disease. 
This research has advanced the latest frontier in 
cancer treatment: immunotherapy. 
Schreiber leads the Andrew M. and Jane 
M. Bursky Center for Human Immunology 
and Immunotherapy Programs, where he and 
many others are dedicated to translating human 
immunology research from the bench to the 
bedside. Much of their work has started in animal 
models. As he put it: “We’ve cured a lot of mice of 
their cancers.” But it’s not only mice who benefit 
from the center’s work.
“One of the things that’s been so exciting is 
that for the first time we have an opportunity to 
take what we’re learning at the bench level and see 
it applied to human disease,” said Schreiber, the 
Andrew M. and Jane M. Bursky Distinguished 
Professor. “That’s what’s so amazing about the 
Bursky Center.”
While Schreiber focuses on cancer, others at 
the center are applying findings about the immune 
system to autoimmune and infectious diseases, such 
as diabetes and the flu.
The center’s seminal cancer immunology 
research is beginning to move from the lab into 
the clinic, thanks to collaborations across the 
School of Medicine — and particularly with the 
Alvin J. Siteman Cancer Center at Barnes-Jewish 
Hospital and Washington University School of 
Medicine, where clinical researchers are working 
on a variety of ways to harness the immune 
system to fight cancer. 
“Figuring out how to use the immune system to 
target cancer cells and not normal cells is something 
many of us have worked on for the last three or four 
decades,” said Timothy J. Eberlein, MD, the Spencer 
T. and Ann W. Olin Distinguished Professor, 
chair of the Department of Surgery and director of 
Siteman Cancer Center. “Now something we only 
dreamed about is becoming a reality.”
Personalized vaccines
One way to train the immune system to recognize 
cancer cells is by using a vaccine. Vaccines work 
by injecting parts of the foreign invader — in this 
case, cancer cells — into patients. The vaccine 
then prompts the immune system to mount an 
attack on that invader. 
William E. Gillanders, MD, professor of 
surgery and Siteman Cancer Center research 
member, led one of the earliest human breast 
cancer vaccine trials. The vaccine contained a 
protein called mammaglobin-A, which is found at 
abnormally high levels in almost all breast cancer 
cells, making it an easy target for the immune 
system. Gillanders and Washington University 
Andrew M. Bursky and his wife, Jane M. Bursky, 
made a significant commitment to name the 
Andrew M. and Jane M. Bursky Center for Human 
Immunology and Immunotherapy Programs.
The speed at which the center is translating 
groundbreaking discovery into new modalities of 
personalized treatment is incredibly exciting.”
               — Andrew M. Bursky, Trustee
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William E. Gillanders, MD, 
senior scientist Xiuli Zhang, MD, 
and colleagues have developed 
breast cancer vaccines now 
in clinical trials. Here, they 
examine blood test results 
indicating study participants’ 
response to a vaccine.
colleagues were the first to study the protein in 
breast cancer and elicit an immune response to it, 
then developed the vaccine based on that work. 
The trial results were promising, but 
mammaglobin-A also is made by certain  
normal cells and can generate an autoimmune 
response to them. So Gillanders, Schreiber and 
others began searching for other, more tumor-
specific vaccine targets.
They found a candidate in proteins called 
neoantigens that exist on the surface of cancer 
cells. Neoantigens, which Schreiber was among the 
first researchers to recognize, are unique to each 
patient’s tumor but, importantly, are not present 
on normal cells. He and Gillanders reasoned that 
the immune system could be trained to recognize 
neoantigens as foreign and to destroy cancer cells 
without harming normal ones. But the challenge, 
said Schreiber, was how to identify each patient’s 
unique neoantigens and determine which were 
most likely to be recognized by the immune system. 
This is where genome sequencing comes in. 
By sequencing patients’ cancer cell genomes and 
comparing them to their normal cell genomes, 
researchers can determine which neoantigens are 
unique to each patient’s tumor and which generate 
the strongest immune response. They can then use 
those neoantigens to make a personalized vaccine.
Gillanders’ group is testing neoantigen vaccines 
in patients with triple negative breast cancer, a 
form that is difficult to treat. They are conducting 
trials that combine the current standard of care 
— surgery, radiation and chemotherapy — with a 
vaccine in the hope of preventing recurrence. 
“Finding the right way to combine traditional 
therapies with immune therapies such as vaccines, 
that’s where things are moving,” said Gillanders.
Neoantigen cancer vaccines represent a truly 
personalized treatment approach; neoantigens vary 
from patient to patient and from tumor to tumor, so 
each patient’s vaccine must be made from scratch. 
That can present challenges with production. 
Winter 2018-19
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Collect patient’s T cells 
and engineer them to 
recognize and kill cancer.
Checkpoint inhibitors
Use antibodies that block 
cell interactions to restore 
immune destruction of tumors.
Monoclonal antibodies
Use antibodies that attach to 
cancer cells to make them 
visible to the immune system.
NK cell therapy
Expose patient’s NK
immune cells to chemicals 
called interleukins to help 
them better fight cancer.
More ways to treat cancer
accines work 
by co-opting a 
disease-causing agent to 
generate or rev up an immune 
response against that disease. 
To avoid harming healthy tissue, a cancer 
vaccine must be generated from an agent 
unique to cancer cells. Among the promising 
candidates are neoantigens — proteins present only 
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“There aren’t many places that can generate 
these products under the kinds of conditions  
that you need to make a vaccine,” said Schreiber.
Fortunately, the School of Medicine and 
Siteman Cancer Center are home to a Good 
Manufacturing Practice (GMP) lab, where 
immunotherapies such as cancer vaccines 
can be made and tested in clinical trials. Such 
facilities, which meet exceedingly high standards 
for consistency and quality, are not typical in 
most academic medical centers and help keep 
costs down when producing such expensive 
individualized treatments.
Deploying T cells
Another form of immunotherapy under 
investigation at the School of Medicine uses a 
patient’s T cells to target certain blood cancers,  
such as leukemia, lymphoma and multiple 
myeloma. T cells typically fight off disease.  
But in some cancer patients, these cells lose the 
ability to recognize and attack cancer cells. 
“The immune system can’t always see cancer 
cells as threats; the T cells are sometimes blind 
to them,” said John F. DiPersio, MD, PhD, the 
Virginia E. and Sam J. Golman Professor of 
Medicine in Oncology and deputy director of 
Siteman Cancer Center. “By modifying T cells, 
we tell them what to look for so they can go right 
to the leukemia or lymphoma and eliminate the 
cancerous cells.” 
Like the cancer vaccines, this therapy is 
individualized for each patient and each tumor. 
The T cells, known as Chimeric Antigen Receptor, 
or CAR-T cells, are produced in the same GMP 
facility where the vaccines are made. They are 
designed and tested by the Center for Gene 
and Cellular Immunotherapy (CGCI) in the 
Department of Medicine’s Division of Oncology.
DiPersio and colleagues were involved in 
clinical trials that led to the Food and Drug 
Administration’s approval of CAR-T cell therapy, 
and Siteman Cancer Center is now among the first 
centers nationwide to offer it to patients. DiPersio’s 
team is now working on a way to make a universal 
form of CAR-T cells that can come from a donor 
rather than the patient. Such an approach could 
be faster, less costly and more effective for patients 
with rapidly progressing blood cancers. DiPersio 
and the CGCI team are attempting to expand 
application of current CAR-T to other diseases, 
such as T-cell leukemias and lymphomas, acute 
myelogenous leukemia and solid tumors. 
Also entering the clinic is a new form of 
immunotherapy called checkpoint inhibitors. 
Checkpoints are proteins on the surface of T cells 
that survey proteins on other cells to determine 
whether they are normal or diseased. Normal 
cells are left alone, and diseased cells are flagged 
for destruction. Unfortunately, cancer cells can 
display proteins that bind to T cell checkpoints 
and trick the T cells so they do not see the 
cancer as foreign. Researchers are now devising 
antibodies that block the T cell-cancer cell 
interactions, making the cancer once again visible 
to the immune system.
The 2018 Nobel Prize in Physiology or  
Medicine went to James P. Allison, PhD, of the 
United States and Tasuku Honjo, MD, PhD, of 
Japan, who independently discovered two separate 
checkpoint inhibitor pathways. At Washington 
University, researchers are using checkpoint 
inhibitors in combination with traditional 
therapies as well as neoantigen vaccines in  
trials for breast, lung and other cancer types.
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The research being conducted at the Siteman Cancer 
Center is transforming the way the disease is treated.” 
    —  Alvin J. Siteman,  
Trustee Emeritus
During Leading Together, Alvin J. and Ruth Siteman continued 
their transformative support for the Alvin J. Siteman Cancer Center 
at Barnes-Jewish Hospital and Washington University School of 
Medicine, which was named in 1999 in honor of their generosity. 
Winter 2018-19
A new standard 
Much of the work on targeted cancer immuno-
therapies could not have been done without the 
Elizabeth H. and James S. McDonnell III Genome 
Institute (MGI). In 2008, the institute led a historic 
effort to sequence the first entire cancer genome, 
of a woman with leukemia, and helped identify the 
genetic errors that contributed to her disease. Though 
it was an uncertain endeavor at the time, St. Louis 
philanthropist Alvin J. Siteman agreed to fund the 
project. That work has since established Washington 
University as a national leader in the field of cancer 
genomics and prompted many clinicians to add 
cancer genome sequencing to their standard of care.
A case in point: Nearly every patient with  
lung cancer who sees Ramaswamy Govindan, MD, 
the Anheuser-Busch Endowed Chair in Medical  
Oncology, gets some or all of their genome sequenced. 
“We no longer stop at the microscopic level 
when diagnosing cancer,” said Govindan, co-leader 
of Siteman Cancer Center’s solid tumor program 
and a leader in lung cancer clinical trials and 
translational research. “Now we do molecular 
profiling and study the genes that are altered to see 
whether we can use targeted therapies.” Depending 
on the situation, that might involve using a targeted 
chemotherapy or customized tumor vaccine, either 
as part of a clinical trial or as a standard of care.
Govindan’s group is trying to understand the 
reasons why cancer cells metastasize or become 
unresponsive to medical therapies. He also is using 
sequencing to develop a neoantigen vaccine that he 
is testing in a trial for patients with non-small cell 
lung cancer, the most common form of the disease.
A FOCUS ON
cancer disparities
One of the best ways to fight cancer is to stop it before it starts, and, failing that, make sure everyone has access to 
the best possible care. Siteman Cancer Center is working with the 
community in and around St. Louis to improve prevention and 
screening programs and to reduce cancer care disparities.
At the forefront of these efforts is Bettina Drake, PhD, MPH, 
associate director of cancer health equity for Siteman Cancer Center.
Drake, an associate professor of surgery in the Division of Public 
Health Sciences, began researching prostate cancer as a doctoral 
student at the University of South Carolina, in a state where 
African-American men are almost three times more likely to die of 
prostate cancer than white men — often due to missed diagnoses. 
The survival rate for prostate cancer, if caught early, is normally 
95-100 percent. 
Soon after her father was diagnosed with prostate cancer,  
Drake got involved in community outreach with area churches, 
providing educational materials about prevention and screening 
for those at risk of getting cancer. “The combination of my  
outreach experiences and my father’s diagnosis fueled my  
interest and passion in disparities research,” said Drake.
In St. Louis, Drake now leads the Prostate Cancer Community 
Partnership, part of the Program for the Elimination of Cancer 
Disparities at Siteman Cancer Center. The program seeks to eliminate 
screening and treatment barriers to improve patient outcomes. 
Drake works with community leaders and colleagues such as 
Lannis Hall, MD, MPH, Arnold D. Bullock, MD, and Aimee S. James, 
PhD, MPH, to develop public awareness campaigns and refine 
identification of high-risk groups. She is also focused on recruiting  
a more diverse patient population for Siteman clinical trials.
“When we do research, we want our patient population to 
resemble the people who will be receiving the treatment in the 
future,” said Drake. 
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Paula C. and Rodger O. Riney made a 
major commitment to establish the 
Paula C. and Rodger O. Riney Blood 
Cancer Research Initiative Fund for 
multiple myeloma research.
With the research that is 
being done, we are getting 
so close. The future looks 
brighter than ever before.”  
    — Rodger O. Riney
Bettina Drake, PhD, 
MPH, discusses cancer 
prevention at a health 
fair in East St. Louis.
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Researchers at MGI and elsewhere at the  
School of Medicine are making key discoveries 
in a number of other cancer types, including 
leukemia, aggressive prostate cancer and estrogen 
receptor positive breast cancer, one of the most 
common forms of that disease. This work is 
helping to guide treatment decisions such as 
choosing the appropriate chemotherapy or 
determining who may be a good candidate for 
certain immunotherapies, such as vaccines.
MGI’s sequencing advances, the Bursky 
Center’s immunology discoveries and Siteman 
Cancer Center’s clinical prowess make for a 
powerful combination. 
“The next frontier in cancer research is to apply 
our skills in genomics to better characterize the 
tumor, its environment and its interaction with 
the immune system,” said DiPersio. “That will be 
a huge help in understanding the relapsing and 
remitting of cancers.” 
“The future is going to be pretty amazing 
for cancer patients. They’ll have more effective 
treatments with fewer side effects, more targeted 
therapies, early diagnosis and even ways to prevent 
the disease,” said Eberlein. “We’ve been fortunate 
to have the partnership of so many donors, 
patients and their families, who have recognized 
that investing in innovation and research is the 
future of cancer care.”
Elizabeth H. and James S. McDonnell III and the JSM Charitable 
Trust made an extraordinary commitment to name the 
Elizabeth H. and James S. McDonnell III Genome Institute.
What appeals to us about the institute is its 
collaboration with St. Louis Children’s Hospital and  
the School of Medicine’s Department of Pediatrics in  
the application of genomics to pediatric cancers.” 
  — James S. McDonnell III
Oncologist John F. DiPersio, 
MD, PhD, meets with cancer 
patient Stephen Brown.
Winter 2018-19
Jeffrey I. Gordon, MD, the founder of 
microbiome research, is also known as 
a dedicated and very influential mentor 
who has trained a next generation of 
leaders in this field. Carrie A. Cowardin, 
PhD, left, and Vanderlene L. Kung,  
MD, PhD, are postdoctoral researchers 
in Gordon’s lab.
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Even in our most solitary moments, we 
humans are never alone. On us and within us, 
tens of trillions of microbes live and thrive — 
not as passive hitchhikers, but as interactive, 
symbiotic shapers of our biology. From the 
time of our births, these microbes are at work, 
establishing distinct communities in many 
regions of our bodies. 
In recent decades, scientists at Washington 
University have led the way in exploring how 
these microbial communities impact human 
health. Their work has shaped a new area of 
study that is revolutionizing our understanding 
of normal human physiology, metabolism, 
immunity, growth and neurodevelopment, as 
well as the roots of many diseases.
Probing the 
microbiome
Studies of people and their companion microbes 
shed light on health and disease
B Y  J U L I A  E V A N G E L O U  S T R A I T
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A new field emerges
Using the gene sequencing technology of the 
genome revolution, along with many other 
experimental and computational methods and 
tools, researchers worldwide are studying our 
microbial companions — considering them not in 
isolation, but rather in the context of the complex 
communities in which they dwell. Scientists are 
learning which microbial members exist in a given 
area of the body, what genes they collectively 
possess, what their genes do, how community 
membership varies from person to person, and 
ultimately, how these communities influence 
health and disease.  
The work has emerged as a new field called 
microbiome research, founded by Jeffrey 
I. Gordon, MD, the Dr. Robert J. Glaser 
Distinguished University Professor and director  
of the Edison Family Center for Genome Sciences 
& Systems Biology at Washington University 
School of Medicine.  
Microbiome is the term given to the collective 
repertoire of genes possessed by microbes in a 
given community. Microbiomes are massive; the 
gut microbiome alone is made up of more than 
100 times the number of genes in the human 
genome. In 30 years of seminal research, Gordon 
has revealed the fundamentals of how these 
communities first assemble, how they adapt, how 
community members cooperate and compete 
with one another, and how they interact with the 
human body. What’s more, he and his students 
were the first to link the gut microbiome to two of 
the world’s most vexing global health problems — 
childhood malnutrition and obesity.
“For human societies to flourish, our challenge 
is to do everything in our power to promote the 
healthy development of children so that they 
may realize their full potential,” said Gordon, 
also professor of pathology and immunology, 
of developmental biology, of medicine and of 
molecular microbiology. “There are dramatic 
disparities in the abilities of children in different 
David Wang, PhD, right, 
and PhD student Luis 
Sandoval are studying 
viruses in the gut to learn 
more about their impact 
on health and disease.
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parts of the world to live healthy lives. And 
somewhere in the midst of this challenge  
to promote healthy development sits the  
gut microbiome.” 
Healthy communities
“No one else was doing this work when Jeff first 
started, and he was alone in the wilderness for 
a long time. Now, myriad microbiome projects 
at Washington University and around the world 
have built on Jeff’s science, in part because he has 
trained many of the next generation of leaders in 
this field,” said Phillip I. Tarr, MD, the Melvin E. 
Carnahan Professor of Pediatrics and professor of 
molecular microbiology.   
Central to the field is learning how 
to nurture microbial communities 
in ways that enhance human health 
— much as one would cultivate the 
natural flora and fauna common to a 
forest or wetland to support a healthy, 
diverse and robust ecosystem. That 
ability could have massive public 
health implications, including checking 
infectious disease, resolving chronic 
inflammatory conditions, correcting 
metabolic dysfunction, and tackling the 
global problems related to the quality 
of our diets and nutrition — all at a 
time of rapid population expansion 
and challenges to environmental 
sustainability.  
“This is a new frontier,” said Tarr, 
also director of the Division of Pediatric 
Gastroenterology, Hepatology, and 
Nutrition. “The rules are now just 
beginning to be written.”
Therapeutic foods 
Central to Gordon’s current work is addressing 
malnutrition. He and his collaborators at the 
International Centre for Diarrhoeal Disease 
Research in Bangladesh have shown that 
children with malnutrition possess gut microbial 
communities that fail to develop normally, leaving 
them with communities that appear younger, 
or less mature, than those of healthy children. 
Moreover, current therapeutic foods do not repair 
this immaturity or correct the long-term effects 
of malnutrition, including impaired growth, 
metabolism, immunity and brain development. 
These findings have led his team to develop 
new therapeutic foods, composed of affordable, 
Medical student 
researcher I-Ling 
Chiang pulls bacterial 
cultures from a freezer 
in the lab of Thaddeus S. 
Stappenbeck, MD, PhD.
The Harry Edison Foundation and the Edison family 
made a major commitment to name the Edison 
Family Center for Genome Sciences & Systems Biology.
The Edison family greatly respects Dr. Gordon’s sound 
thinking and innovative research. His work has global 
importance and appears to be critical to helping 
malnourished children throughout the world.”                   
      —  Andrew E. Newman, Life Trustee  
and Edison family member
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the gut microbiomes of babies born prematurely. 
These babies are at risk of developing a potentially 
deadly condition called necrotizing enterocolitis, 
a progressive inflammatory process that begins 
inside the gut and causes tissue death. Sometimes 
antibiotics are an effective treatment, but some 
babies need surgery to remove dead tissue. Even 
with these aggressive therapies, about 30 percent 
of babies who develop the disease die from this 
catastrophic event. 
Tarr and Warner have shown that babies who 
develop necrotizing enterocolitis have a different 
mix of microbes in their intestines than babies 
who never develop the disease. 
“We’re still in the earliest stages of defining 
which microbes are good and which are bad,” Tarr 
said. “But broadly, we want to find out what factors 
make it likely for good microbes to get into the gut 
and stay and, similarly, what factors help the body 
get rid of bad microbes. The hope is to ultimately 
protect premature infants from ever developing 
this terrible disease.” 
The virus hunters
Tarr and his colleagues — including David Wang, 
PhD, professor of molecular microbiology and of 
pathology and immunology, and Lori R. Holtz, 
MD, MSPH, associate professor of pediatrics — 
also have studied viruses living in the guts of 
healthy newborns. The viruses’ collective genetic 
material is called the virome.
“Not only are there many viruses in the 
digestive systems of infants that we had no idea 
were present, there are viruses that infect the 
bacteria in great numbers,” Tarr said. “And this 
almost certainly plays a role in how the bacterial 
community develops.” 
Indeed, the bacteria, viruses and other 
microbes in the intestine together offer a picture 
of the gut environment that metaphorically 
resembles a backcountry wilderness. 
And as they explore that wilderness, Wang and 
his team have viruses in their sights. Wang seeks 
out previously unstudied viruses to understand 
how they function and to learn more about how 
viruses cause disease. 
“We want to understand the nature of the 
whole virome and how it may be associated with 
health or disease,” Wang said. “We’ve done this 
in the context of a number of diseases, including 
acute diarrhea, HIV/AIDS, type 1 diabetes and 
culturally acceptable components that advance 
development of immature gut communities and 
improve the health status of malnourished children.
Their work is not only establishing a vital 
link between formation of healthy microbial 
communities and healthy growth, but also is 
revealing how microbial communities transform 
components of the foods we consume into 
products that influence numerous features of  
human postnatal development. At the same 
time, food science is revealing more about the 
components of various food staples and how plant 
genetics and food processing technologies and 
consumers’ microbiomes influence the nutritional 
content and value of those foods. Together, these 
advances should enable discovery, development 
and deployment of entirely new health-promoting 
foods and better dietary recommendations for 
children and their parents, Gordon said.
Preventing disease 
Beyond Gordon’s lab, Washington University 
microbiome researchers are addressing other topics. 
Tarr and colleagues Barbara B. Warner, MD, 
professor of pediatrics, and Gautam Dantas, PhD, 
professor of pathology and immunology and of 
molecular microbiology, for example, are studying 
Thaddeus S. Stappenbeck, MD, PhD, right, reviews slides 
with postdoctoral fellow Umang Jain, PhD. 
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inflammatory bowel disease. This has been 
fascinating because we had no idea what to expect.”
Working with Thaddeus S. Stappenbeck, MD, 
PhD, the Conan Professor of Laboratory and 
Genomic Medicine, Wang and colleagues found 
that the virome in patients with inflammatory 
bowel disease is different than the virome of 
healthy people, suggesting viruses may play a  
role in the development of this condition.
Guardians of the gut
Stappenbeck’s work examines the interaction of 
gut microbes and human gut tissues, including 
agents he calls “guardians of the gut.” One such 
agent is an antibody called immunoglobulin A, 
or IgA. IgA coats gut microbes and may well 
calm the response of our immune system to the 
microbiome. Another is a cell type in the gut 
lining known as Paneth cells.
“These cells protect the inner lining of the 
gastrointestinal tract by making a variety of 
antimicrobial proteins,” said Stappenbeck, also a 
professor of developmental biology and a former 
postdoctoral fellow in Gordon’s lab. “In doing so, 
they help shape the microbiome present in the gut. 
We know that mice with defective Paneth cells can 
develop worsened gut inflammation. This suggests 
that we can use the genetics of the abnormal 
Paneth cells to diagnose the type of inflammatory 
bowel disease a patient might have.”
A better understanding of these guardians and 
others may contribute to better ways to diagnose, 
treat or prevent inflammatory diseases of the gut.
As scientists study the gut microbiome, 
additional complexity reveals itself. But if 
researchers can navigate that complexity to 
understand and promote a healthy gut ecosystem, 
their work may save preemies from a deadly 
inflammatory disease, prevent the complications 
of obesity, or protect children from the ravages of 
malnutrition. Nurturing a healthy gut may be the 
next public health revolution. 
Debra and George W. Couch III provided significant 
campaign support for research in personalized medicine;  
in their honor, the university named the Debra and 
George W. Couch III Biomedical Research Building. 
If we are able to help mitigate suffering 
in any way, that’s a larger contribution 
to humanity than Debra and I ever 
envisioned we would have. We feel very 
fortunate that we can do something 
that has such potential to help others.” 
     — George W. Couch III, Trustee
Barbara B. Warner, MD, 
left, Lori R. Holtz, MD, 
MSPH, and Phillip I. 
Tarr, MD, discuss their 
research on gut microbial 
communities in premature 
and healthy newborns.
Winter 2018-19
Research technician Ira 
Wight, left, and  PhD student 
Arielle Homayouni examine 
microscopic samples related 
to autophagy, a natural cell 
recycling process.
Emerging areas 
New centers address  
personalized medicine 
and aging T
hree newly established research centers  
will strengthen the School of Medicine’s 
commitment to advancing two of the  
institution’s major research priorities: personalized  
medicine and aging. Investigators in these centers  
will undertake multidisciplinary work with implications  
for addressing a broad range of major health issues.
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Personalized  
cardiovascular care
Despite years of advances in the treatment and 
prevention of cardiovascular disease, it remains 
the leading cause of death worldwide. Now, 
personalized medicine — an innovative approach 
based on individual genetics and biomarkers —  
has the potential to change the standard of care. 
Alumnus Kim D. Kuehner, MBA ’77, has 
committed $15 million to establish and endow 
the Kim D. Kuehner Program for Personalized 
Cardiovascular Medicine in the School of 
Medicine. The program will fund competitive 
research grants within the school, providing a 
permanent source of funding for research aimed 
at improving the prevention, diagnosis and 
treatment of heart disease. 
The complexities of cardiovascular diseases 
such as heart failure, atherosclerosis and 
cardiomyopathy make developing personalized 
medicine approaches challenging. At the center, 
researchers hope to elucidate 
the mechanisms behind each 
disease to enable development of 
therapies tailored for certain patient 
subgroups — ending the approach 
of treating the “average patient.” 
Ultimately, clinicians will address 
the cause of the disease rather than 
the presenting clinical symptoms. 
“Individualized patient care strategies have 
transformed the care of patients with cancer,” 
said Douglas L. Mann, MD, the Tobias and 
Hortense Lewin Professor of Medicine and chief 
of the Cardiovascular Division. “Thanks to Kim 
Kuehner, investigators involved in cardiovascular 
disease at Washington University will now have 
the opportunity to transform the care of patients 
afflicted with heart disease.”
The Kuehner program comes at the perfect 
time, as the School of Medicine ushers in the next 
phase of its personalized medicine initiative.
“This new program will allow us to leverage our 
leadership in personalized medicine to develop 
tailored approaches to cardiovascular disease,” 
said David H. Perlmutter, MD, executive vice 
chancellor for medical affairs and the George and 
Carol Bauer Dean of the School of Medicine. “Mr. 
Kuehner’s exceptional generosity and deep interest 
in addressing a significant health challenge will 
benefit patients around the globe.”
Aging and age–dependent 
degenerative diseases
Sima Needleman and Philip Needleman, PhD, 
former chair of the Department of Pharmacology, 
have committed $15 million to establish the Sima 
and Philip Needleman Center for Autophagy 
Therapeutics and Research and the Philip and 
Sima Needleman Center for Neurometabolism and 
Axonal Therapeutics. The combined research efforts 
are expected to foster development of novel therapies 
for multiple diseases and impact neurodegenerative 
diseases of aging such as Alzheimer’s.
“Part of my vision for this school is to have a major 
impact on aging. It touches research underway in 
every department,” said Perlmutter. “These centers 
will support us in advancing shared priorities and 
making progress towards real, measurable outcomes.”
The Center for Autophagy Therapeutics and 
Research, led by Perlmutter, will focus its efforts on 
autophagy — the mechanism by which cells break 
down and recycle their contents. Recent studies 
show that exercise and caloric restriction promote 
autophagy, resulting in better health and increased 
longevity. But when the process becomes impaired, 
which is increasingly likely with age, abnormal 
cellular activity can lead to cancer, diabetes and 
neurological disorders. 
The Center for Neurometabolism and Axonal 
Therapeutics will be led by Jeffrey Milbrandt, 
MD, PhD, James S. McDonnell Professor and 
head of the Department of Genetics, and Aaron 
DiAntonio, MD, PhD, Alan A. and Edith L. Wolff 
Professor of Developmental Biology. Building on 
recent breakthroughs in understanding how nerves 
degenerate, the center will explore the intersection 
of metabolism, inflammation and degeneration 
in the nervous system in order to develop novel 
therapies for neurological diseases.
Needleman began his career at the School of 
Medicine in 1964 as a postdoctoral fellow and 
later held several pivotal roles there. He spent 14 
years at Monsanto, later Pharmacia LLC, heading 
pharmaceutical research and development. Building 
on research begun at Washington University, he led 
the development of the arthritis drug Celebrex. 
 
“ These centers will support us in advancing  
shared priorities and making progress towards  
real, measurable outcomes.”   — David H. Perlmutter, MD
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Campaign 
summary
32  Washington University School of Medicine
A successful campaign is supporting scientists, 
teachers and learners as they change the future of 
medicine locally and around the globe.
Including the George and Carol Bauer Dean of the 
School of Medicine. The inaugural recipient is 
David H. Perlmutter, MD, also Spencer T. and Ann 
W. Olin Distinguished Professor and executive vice 
chancellor for medical aairs














Faculty Endowment: $360M 
supporting endowed professorships
Student Endowment: $47.7M 
supporting endowed student scholarships
Academic Programs: $1,337M 
supporting critical programs and research
Facilities: $56.8M 
supporting capital improvements
Annual Fund: $44.5M 
supporting teachers and learners
































$ 1.34B  
Academic  
Programs 
supporting critical  
programs and research
RESEARCH  The Debra and George W. Couch III Biomedical Research Building, 
named in recognition of significant campaign support from Debra and George 
W. Couch III, is home to numerous research initiatives and centers, including the 
Edison Family Center for Genome Sciences & Systems Biology, the Center for Cellular 
Imaging, the Center for Multiple Myeloma Nanotherapy, the Optical Radiology Lab 
and the Molecular Imaging Center.
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Including the George and Carol Bauer Dean of the 
School of Medicine. The inaugural recipient is 
David H. Perlmutter, MD, also Spencer T. and Ann 
W. Olin Distinguished Professor and executive vice 
chancellor for medical aairs
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Including the George and Carol Bauer Dean of the 
School of Medicine. The inaugural recipient is 
David H. Perlmutter, MD, also Spencer T. and Ann 
W. Olin Distinguished Professor and executive vice 
chancellor for medical aairs
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established during the campaign 
included a named deanship, making 
David H. Perlmutter, MD, the inaugural George 
and Carol Bauer Dean of the School of Medicine. 
EDUCATION  Medical students Tiffany J. Wu, Jason A. Morris, 
Jae Lee and Jane M. Hayes, all Distinguished Alumni Scholarship 
recipients, are among hundreds of graduate students at the  
School of Medicine supported by scholarship donations.
PATIENT CARE  The School of 
Medicine’s patient care mission has 
flourished during the 10-year campaign 
period, which ended in summer 2018. 
The number of clinical practice sites 
grew from 35 to 49, clinical revenues 
nearly doubled, and two 12-story 
towers — carefully designed to support 
patient comfort and optimal care — 
opened on the Medical Campus, offering 
facilities for patients of Siteman Cancer 
Center and the Women & Infants Center. 












Zealand Endocrine Surgeons, and also the 
Asian Association of Endocrine Surgeons. 
This is the first time a woman has led either 
organization. She is married with three 
children, ages 12, 14 and 15.
Jamey Gordon, PT ’97, DPT ’07, is director 
of athlete development and a partner at 
Pro X Athlete Development in Westfield, 
Ind. Pro X specializes in sports performance 
training, skill development, rehabilitation 
and recovery in all sports. The partners 
planned to open a 55,000-plus-square-foot 
facility in late 2018 in Westfield, Ind. Gordon 
will continue to serve as a clinical instructor 
and fellowship mentor for the Program in 
Physical Therapy at WUSM.
2000S
Armand Antommaria, MD ’00, was 
promoted to professor in the Department 
of Pediatrics at Cincinnati Children’s 
Hospital Medical Center and the University 
of Cincinnati School of Medicine. He is the 
director of the Ethics Center at Children’s.
Emily Bannister, 
LA ’96, MD ’01, and 
her husband, David, 
welcomed twins Abigail 
and David to their family 
in April 2017. They join 
big sister, Lucy, born 
in July 2015. Bannister 
is an attending in the HealthPartners 
Occupational Medicine residency program 
in St. Paul, Minn., and serves as medical 
liaison for laboratory biosafety at the 
University of Minnesota.
Katie Grover, DOT ’03, and her husband, 
Ben, welcomed a child, Mason, Jan. 6, 2018.
Brian J. DeBosch, MD/PhD ’08, is one 
of five faculty members at the School 
of Medicine elected to the Society for 
Pediatric Research, which aims to improve 
child health through research, professional 
collaboration and advocacy.
2010S
Kristin Haider Chumbley, AuD ’10, was 
married June 22, 2018.
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1960S 
Harvey Michael “Mike” Jones, MD ’66,  
was elected vice president of the American 
Osler Society and will serve a three-year 
term, including one year as president. 
The American Osler Society is a history 
of medicine organization that seeks 
to advance a humanistic approach to 
medicine. A retired clinical professor of 
pathology and laboratory medicine at the 
University of North Carolina at Chapel Hill, 
Jones also recently was selected by high 




MD ’70, stepped down 
after nearly 40 years as a 
division chief of neonatal 
perinatal medicine at 
the University of Texas, 
San Antonio, and then 
at the University of 
Oklahoma. She became professor emeritus 
in fall 2017. Escobedo was named a 2018 
Distinguished Alumnus at Baylor University, 
where she completed her undergraduate 
study. Escobedo spends summers in East 
Hampton, N.Y., and winters in San Antonio.
Barbara Seaworth, MD ’77, a professor of 
medicine at The University of Texas at Tyler, 
has been awarded grants exceeding $30 
million in the last 10 years, the most recent 
from the Centers for Disease Control and 
Prevention (CDC) in 2018. She is director of 
the Heartland National Tuberculosis Center 
in San Antonio, Texas. The CDC recognized 
Seaworth as a 2018 National Physician 
TB Champion for treating patients and 
providing education programs to caregivers 
who treat the disease. She was named 
by the San Antonio Business Journal as a 
2018 Health Care Hero. Seaworth was in 
the Marshall Islands during summer 2018 
to screen for and treat tuberculosis in that 
island nation. She also runs marathons and 
tries to keep up with her six children and 
husband, John Seaworth, MD ’76, as well 
as their six grandchildren.
Gregorio A. Sicard, MD, HS ’78, professor 
emeritus of surgery at WUSM, was awarded 
the Lifetime Achievement Award from the 
Society for Vascular Surgery in 2018. Sicard 
was on the WUSM faculty for more than 
three decades and started the vascular 
surgery section in 1983, the first year the 
American Board of Surgery certification in 
vascular surgery became available. Under 
Sicard’s leadership, the section grew from 
performing fewer than 300 procedures 
annually to becoming a globally recognized 
center in endovascular patient care and 
research. He retired in 2015. 
Richard L. Wahl, MD ’78, HS ’83, received 
the 2018 Georg Charles de Hevesy Award 
from the Society of Nuclear Medicine and 
Molecular Imaging. The award recognizes 
researchers whose groundbreaking 
discoveries have advanced nuclear 
medicine.
1980S 
Nancy L. Bartlett, MD ’86, the Koman Chair 
in Medical Oncology at WUSM, has been 
named a 2018 Legacy Leadership Award 
honoree by the Gateway Chapter of the 
Leukemia & Lymphoma Society.
1990S 
Bradley L. Schlaggar, MD/PhD ’94, HS ’96, 
HS ’99, has been named president and CEO 
of the Kennedy Krieger Institute in Baltimore, 
Md. The institute works to improve the lives 
of children and adolescents with disorders 
and injuries of the brain, spinal cord and 
musculoskeletal system. He spent 19 years 
on the WUSM faculty; during his tenure, he 
served as director of the pediatric neurology 
residency program, division head of pediatric 
and developmental neurology, neurologist-
in-chief at St. Louis Children’s Hospital, 
and co-director of the Intellectual and 
Developmental Disabilities Research Center.
Julie Miller, MD ’96, has been living 
in Melbourne, Australia, since finishing 
surgical training in 2001. Miller, an 
academic endocrine surgeon, recently was 
elected president of Australian and New 
C L A S S N O T E S
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Danielle Doria Braman, 
OT ’11, announces the 
birth of her first daughter, 
Elliana, on March 15, 
2018. Braman is working 
at Children’s Hospital 
Colorado.
Ian Glenn, MD ’12, and Tara Glenn,  
MD ’12, welcomed a daughter, Nora  
Mary, on July 14, 2018.
Jennifer Yu, EN ’08, MD ’12, MPHS ’15, 
a general surgery resident at WUSM and 
Barnes-Jewish Hospital, has received a 
2018 Outstanding Resident Teacher Award 
from the Association for Surgical Education. 
Yu’s award recognizes her enthusiasm, 
effectiveness and commitment to teaching 
surgical skills to medical students and 
other residents. 
Samuel Nemanich, MS/PhD ’16, is  
listed as co-principal investigator on a 
grant awarded from the National Center  
of Neuromodulation for Rehabilitation,  
a National Institutes of Health (NIH)- 
funded project. Nemanich and his wife, 
Sarah Wahlstrom Helgren, PhD ’16,  
also welcomed their second child, Lucille, 
on July 25, 2018.
Brandon Holmes,  
MD/PhD ’17, married 
Diane Snyder, OT ’10, 
on April 14, 2018. Both 
work at the University of 
California, San Francisco, 
where Brandon is a 
neurology resident 
physician and Diane is a practicing 
occupational therapist.
Matthew McCoy,  
PhD ’18, and  
Amy Herbert, PhD ’18, 
were married  
June 30, 2018. 
The couple met at 
Washington University 
while working on PhDs 
in biology and biomedical sciences.  
They are Grass Fellows in Neuroscience  
at the Marine Biological Laboratory in 
Woods Hole, Mass., and will be moving 
to Stanford University in fall 2018 as 
postdoctoral researchers.
Joseph J. Billadello, MD, a professor of medicine and director  
of the Adult Congenital Heart Disease Center, died Wednesday, 
Aug. 8, 2018, following a long battle with multiple myeloma.  
He was 65.
Billadello came to Washington University in 1981 as a 
cardiology fellow and joined the School of Medicine faculty, 
where, over his long career, he cared for patients with heart 
disease, especially adults living with congenital heart disease. He also helped lead 
several organizations focused on treating individuals born with heart defects who 
survive to adulthood and require specialized care.
“Joe’s leadership of the Adult Congenital Heart Disease Program culminated in the 
designation of the Washington University program as an accredited comprehensive 
care center by the Adult Congenital Heart Association, one of only a few such centers 
in the nation,” said Victoria J. Fraser, MD, the Adolphus Busch Professor and head of 
the Department of Medicine. “Joe was passionate about patient care, and that is 
reflected in the quality of care he and his colleagues provided.”
Billadello earned a medical degree from Georgetown University School of 
Medicine in 1978. He completed an internship and residency in internal medicine  
at Duke University before coming to Washington University for fellowship training.
He is survived by his wife, Guadalupe Sanchez, MD; mother, Julia “Peggy” 
Billadello; sister, Joan Quinn; daughter, Laura Billadello, MD; and son-in-law,  
Michael DeVita, MD.
John O. Holloszy, MD, whose research led to advances in  
the understanding of the body’s response to exercise, died 
Wednesday, July 18, 2018, in Town and Country, Mo., following 
a long battle with kidney disease. He was 85.
A 1957 alumnus of the School of Medicine, Holloszy  
went on to train as a postdoc at the school under Nobel 
laureate Carl F. Cori, MD. In 1973, Holloszy became the director 
of the school’s Division of Applied Physiology in the Department of Preventive 
Medicine, and later served as director of the Division of Geriatrics and Gerontology  
in the Department of Medicine. He retired from the university in 2017.
Holloszy’s studies of aerobic exercise, nutrition and muscle development 
changed the way elite athletes train and helped others better cope with heart 
disease, diabetes, obesity and aging.
Holloszy also discovered that exercise improved insulin sensitivity in patients 
with type 2 diabetes, and that exercise training could reverse some of the damage 
in patients with coronary heart disease. In key animal studies, Holloszy found that 
calorie restriction lengthened the animals’ lives even more than exercise.
“John Holloszy is considered the father of modern exercise biochemistry,” said 
Samuel Klein, MD, the William H. Danforth Professor of Medicine and Nutritional 
Science and director of the Division of Geriatrics and Nutritional Science. 
In 2000 at the Olympic Games in Sydney, the International Olympic Committee 
presented Holloszy with a gold medal, the IOC Olympic Prize in Sports Medicine, 
for his contributions to understanding the science behind enhanced athletic 
performance and disease state management.
Born in Vienna, Holloszy earned a bachelor’s degree in 1953 at Oregon  
State University. 
Holloszy is survived by his wife, Violetta, and a brother, Fred. 
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1940S 
Richard Bell, DE ’46; July ’18
Martha Benedict, OT ’47; June ’18
Virginia P. Hagemann, NU ’48; July ’18
Homer H. Hanson, HS; Apr. ’18
Richard C. Lyon, DE ’47; Apr. ’18
Ruth Portman Steele, OT ’48; Aug. ’18
1950S
David J. Edwards, MD ’57; July ’18
Stephen M. Harris, HS ’54; Apr. ’18
Frank A. Howard, MD ’50; Apr. ’18
Daniel B. Lowrey, MD ’50; June ’18
Muriel MacKallor, OT ’53; Apr. ’18
Morris Reichlin, LA ’55, MD ’59; July ’18
Joseph Sanker, DE ’55; Apr. ’18
Richard L. Swarm, LA ’49, MD ’50; June ’18
Paul D. Tinnin, DE ’54; July ’18
Milton M. Tofle, LA ’51, DE ’55; Aug. ’18
Stephen L. Washburn, MD ’52; June ’18
1960S
Ray Bowman Duncan, HS ’65; June ’18
Darlene A. Feser, NU ’64, GN ’66; July ’18
Cleveland M. McCarty, DE ’61; July ’18
Paul K. Orsay, HS ’67; May ’18
Robert E. Smith, DE ’63; June ’18
1970S
Clinton N. Corder, MD ’71; Apr. ’18
Steven Levitt, LA ’66, DE ’70; June ’18
Michael O. Williams, MD ’74; Aug. ’18
1990S
Darlene Eyster, LA ’75, HS ’95; June ’18
David M. Peeples, HS; June ’18
J. Russell Little, MD, professor emeritus of medicine, died Saturday, 
Aug. 18, 2018, in St. Louis following a long illness. He was 87.
Little served on the School of Medicine faculty from 1964 to 2005 
and as chief of infectious diseases at Jewish Hospital from 1967 to 1996.
He was known for his dedication to teaching, mentoring and 
patient care. In 2017, the Division of Infectious Diseases established 
the J. Russell Little Award for Excellence in Teaching in his honor.
“His compassion and expertise were remarkable, and he was a 
significant reason why the infectious diseases program here is one of the best in the 
country,” said William G. Powderly, MD, the Larry J. Shapiro Director of the Institute of 
Public Health and co-director of the Division of Infectious Diseases.
Little helped characterize the structure of antibodies and contributed to an 
understanding of how they recognize their targets. He also studied how the fungus 
Histoplasma survives inside immune cells, and showed that the antifungal medication 
amphotericin B changes the behavior of the immune system.
He earned a medical degree from the University of Rochester and completed a 
medical residency at Barnes Hospital in 1957. Following a research appointment at the 
National Institutes of Health (NIH), he returned to St. Louis as chief resident at Barnes Hospital. 
He is survived by his daughters, Nancy Little and Susan Little; son, Bryan Little; and 
four grandchildren. 
James C. Warren, MD, 
professor emeritus and 
former head of the 
Department of Obstetrics 
and Gynecology, died 
Saturday, July 21, 2018, 
at his home in Mobile, 
Ala. He was 88.
Warren, a renowned researcher, clinician 
and teacher, was noted for his work in the 
endocrinology and biochemistry of 
reproduction. One of Warren’s most 
important research contributions was 
identifying and determining the significance 
of progesterone, a hormone that is an 
essential part of birth control pills.
Warren earned a medical degree from the 
University of Kansas in 1954. Following an 
internship at the University of Kansas 
Medical Center, he served as a physician in 
the U.S. Navy for two years. Warren then 
completed a residency in obstetrics and 
gynecology and a doctorate in biochemistry, 
both at the University of Nebraska. For 10 
years, he served as a professor of obstetrics 
and gynecology and of biochemistry at the 
University of Kansas School of Medicine. He 
joined the School of Medicine faculty in 1971 
and served as a department head until 1989.
He is survived by his wife, Margie; his 
sister, Kay Ross; three children, Jamie 
Warren Corkran, James Douglas Warren and 
Allison Warren; and nine grandchildren.
 
For full obituaries, visit: 
wumcnews.org/obits
Necita Llorin-Roa, MD,  
a practicing anesthe-
siologist in St. Louis for 
nearly 50 years, died of 
natural causes Sunday, 
May 27, 2018, at St. Luke’s  
Hospital in Chesterfield, 
Mo. She was 74. 
After graduating from the University of 
the Philippines Manila College of Medicine 
in 1969, she completed an anesthesia 
residency and fellowship at Barnes-Jewish 
Hospital and the School of Medicine in 
1973-1974. 
A renowned educator and clinician and 
a beloved colleague, Roa was an associate 
professor of anesthesiology and served on 
the Washington University faculty for 42 
years. She endowed the Necita Roa Award 
for the best graduating anesthesiology 
resident as well as a fund to support global 
health programs for anesthesiology 
trainees. Since 2014, Roa was president of 
the Philippine Medical Association of the 
Greater St. Louis Medical Foundation Inc., 
leading six annual medical and surgical 
missions to underprivileged communities in 
her home country of the Philippines. 
The widow of the late microbiologist 
Renan C. Roa, who immigrated with her 
from the Philippines to the U.S. in 1969, Roa 
is survived by her brothers Carlos Llorin Jr. 
and Manuel Llorin and sister Marilu Arellano. 
O B I T U A R I E S
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Correction: Jacquelyn Carter Kremer, OT ’97, 
was incorrectly listed among the deceased in 
the Fall 2018 Outlook issue.  
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